BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34914188)

  • 1. Pyrimidine: An elite heterocyclic leitmotif in drug discovery-synthesis and biological activity.
    Nadar S; Khan T
    Chem Biol Drug Des; 2022 Dec; 100(6):818-842. PubMed ID: 34914188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Overview of the Synthetic Route to the Marketed Formulations of Pyrimidine: A Review.
    Kumar A; Siwach A; Verma P
    Mini Rev Med Chem; 2022; 22(6):884-903. PubMed ID: 34629043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature.
    Kaur R; Kaur P; Sharma S; Singh G; Mehndiratta S; Bedi PM; Nepali K
    Recent Pat Anticancer Drug Discov; 2015; 10(1):23-71. PubMed ID: 25230072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
    Wang S; Yuan XH; Wang SQ; Zhao W; Chen XB; Yu B
    Eur J Med Chem; 2021 Mar; 214():113218. PubMed ID: 33540357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Relationships of Pyrimidine Derivatives and their Biological Activity - A Review.
    Natarajan R; Anthoni Samy HN; Sivaperuman A; Subramani A
    Med Chem; 2022; 19(1):10-30. PubMed ID: 35579151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrimidine-fused Derivatives: Synthetic Strategies and Medicinal Attributes.
    Joshi G; Nayyar H; Alex JM; Vishwakarma GS; Mittal S; Kumar R
    Curr Top Med Chem; 2016; 16(28):3175-3210. PubMed ID: 27150371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chemistry and biological activity of heterocycle-fused quinolinone derivatives: A review.
    Shiro T; Fukaya T; Tobe M
    Eur J Med Chem; 2015 Jun; 97():397-408. PubMed ID: 25532473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Appraisal on Synthetic and Medicinal Aspects of Fused Pyrimidines as Anti Neoplastic Agents.
    Rani I; Kaur N; Goyal A; Sharma M
    Anticancer Agents Med Chem; 2023; 23(5):525-561. PubMed ID: 35786337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.
    Jadhav M; Sankhe K; Bhandare RR; Edis Z; Bloukh SH; Khan TA
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Application of Pyrrolo[2, 3-d]pyrimidine Scaffold in Medicinal Chemistry from 2017 to 2021.
    Liang T; Yang Y; Wang J; Xie Z; Chen X
    Mini Rev Med Chem; 2023; 23(10):1118-1136. PubMed ID: 36635929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the chemical and biological diversity of heterocyclic systems incorporating pyrimido[1,6-
    Elattar KM; Mert BD; Monier M; El-Mekabaty A
    RSC Adv; 2020 Apr; 10(26):15461-15492. PubMed ID: 35558641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery.
    Khwaza V; Mlala S; Oyedeji OO; Aderibigbe BA
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33918996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating.
    Bandyopadhyay D; Banik BK
    Curr Med Chem; 2017; 24(41):4596-4626. PubMed ID: 28240166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery.
    Li W; Zhang J; Wang M; Dong R; Zhou X; Zheng X; Sun L
    Curr Top Med Chem; 2022 Mar; 22(4):284-304. PubMed ID: 35021973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Development of Pyrimidine-Containing Antimicrobial Agents.
    Zhuang J; Ma S
    ChemMedChem; 2020 Oct; 15(20):1875-1886. PubMed ID: 32797654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
    Cherukupalli S; Karpoormath R; Chandrasekaran B; Hampannavar GA; Thapliyal N; Palakollu VN
    Eur J Med Chem; 2017 Jan; 126():298-352. PubMed ID: 27894044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application and synthesis of thiazole ring in clinically approved drugs.
    Niu ZX; Wang YT; Zhang SN; Li Y; Chen XB; Wang SQ; Liu HM
    Eur J Med Chem; 2023 Mar; 250():115172. PubMed ID: 36758304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Review on Journey of Pyrrole Scaffold Against Multiple Therapeutic Targets.
    Mir RH; Mir PA; Mohi-Ud-Din R; Sabreen S; Maqbool M; Shah AJ; Shenmar K; Raza SN; Pottoo FH
    Anticancer Agents Med Chem; 2022; 22(19):3291-3303. PubMed ID: 35702764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer potential and structure activity studies of purine and pyrimidine derivatives: an updated review.
    Manna T; Maji S; Maity M; Debnath B; Panda S; Khan SA; Nath R; Akhtar MJ
    Mol Divers; 2024 Jun; ():. PubMed ID: 38856835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic drug potential of oxazolo[5,4-d]pyrimidines and oxazolo[4,5-d]pyrimidines.
    Zhirnov VV; Velihina YS; Mitiukhin OP; Brovarets VS
    Chem Biol Drug Des; 2021 Oct; 98(4):561-581. PubMed ID: 34148293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.